| |
Entecavir, New Hep B Drug, BMS Files NDA with FDA
|
| |
| |
Press release issued by BMS today sent to you for your information.
"BRISTOL-MYERS SQUIBB SUBMITS APPLICATIONS IN U.S. AND EUROPE TO MARKET ENTECAVIR, AN INVESTIGATIONAL ANTIVIRAL TREATMENT FOR CHRONIC HEPATITIS B INFECTION"
PRINCETON, NJ-- OCTOBER 4, 2004 -- Bristol-Myers Squibb Company (NYSE: BMY) today announced the submission of a New Drug Application to the U.S. Food and Drug Administration for entecavir, an investigational antiviral agent under development for the treatment of chronic Hepatitis B. In the European Union, the Company also submitted a marketing authorization application for entecavir to the European Medicines Evaluation Agency.
Entecavir is an investigational oral antiviral discovered at Bristol-Myers Squibb that is designed to selectively inhibit the Hepatitis B virus, blocking all three steps in the replication process.
Bristol-Myers Squibb is a global pharmaceutical and related health care products company whose mission is to extend and enhance human life.
Contacts:
David M. Rosen
Bristol-Myers Squibb
Phone: 609-252-5675
Pager; 866-308-4484
david.m.rosen@bms.com
Patrice Grand
Bristol-Myers Squibb
Phone: +33 158836706
Mobile: +33 686427585
patrice.grand@bms.com
|
|
| |
| |
|
|
|
